XORTX Therapeutics Inc (XRTX)

NASDAQ: XRTX · IEX Real-Time Price · USD
1.71
-0.09 (-5.00%)
At close: Jan 21, 2022 4:00 PM
1.67
-0.04 (-2.34%)
After-hours:Jan 21, 2022 5:31 PM EST

Company Description

XORTX Therapeutics Inc., a bio-pharmaceutical company, engages in the development and commercialization of therapies to treat progressive kidney diseases, hypertension, insulin resistance, and diabetic nephropathy.

It develops XRx-008, a late clinical stage program therapy for autosomal dominant polycystic kidney disease; XRx-101, an uric acid lowering agent used to treat patients infected with the coronavirus COVID-19 infection and suppression of acute kidney injury and associated health consequences; and XRx-221, a xanthine oxidase inhibitor candidates for the treatment of diabetic nephropathy.

The company has a partnership with the Icahn School of Medicine to study the incidence of acute kidney injury and hyperuricemia in patients hospitalized with COVID-19.

XORTX Therapeutics Inc. is headquartered in Vancouver, Canada.

XORTX Therapeutics Inc
CountryCanada
Founded2011
IndustryBiotechnology
SectorHealth Care
CEOAllen Davidoff

Contact Details

Address:
Suite 4000, 421 - 7th Avenue SW
Calgary, Alberta T2P 4K9
Canada
Phone14036072621
Websitexortx.com

Stock Details

Ticker SymbolXRTX
ExchangeNASDAQ
Fiscal YearJanuary - December
Reporting CurrencyUS Dollars
CIK Code0001729214

Key Executives

NamePosition
Dr. Allen Warren Davidoff Ph.D.Founder, Chief Executive Officer, President and Director
Amar KeshriChief Financial Officer
Nick RigopoulosDirector of Communications
Dr. David Sans M.B.A., Ph.D.Director of Corporate Development
Dr. Stephen Haworth M.D., MRCPChief Medical Officer
Charlotte MayCorporate Secretary

Latest SEC Filings

DateTypeTitle
Jan 10, 20226-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Dec 21, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Dec 21, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Dec 10, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Dec 9, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Dec 2, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Nov 26, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Nov 23, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Nov 23, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
Nov 9, 20216-KReport of foreign issuer [Rules 13a-16 and 15d-16]
View All SEC Filings